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Lack of human exposure data is frequently reported as a
critical gap in risk assessments of environmental pollutants,
especially regarding “new” pollutants. The objectives of
this study were to assess serum levels of the persistent
2,2′,4,4′,5,5′-hexachlorobiphenyl (CB-153), hydroxylated
polychlorinated biphenyl metabolites (OH-PCBs), polybromi-
nated diphenyl ethers (PBDEs), and hexabromocyclodode-
canes (HBCDDs) in a group of Swedish middle-aged and
elderly women expected to be relatively highly exposed, and
to evaluate the impact of potential determinants (e.g.,
fish intake, age) for the inter-individual variation, as well
as to investigate the association between these pollutants
and bone density. No associations were found between
bone mineral density or biochemical markers of bone
metabolism and the analyzed environmental pollutants.
Relatively high levels of CB-153 (median 260 ng/g fat) and “3-
OH-PCBs (median 1.7 ng/mL serum), and low concentrations
of “6PBDEs (median 3.6 ng/g fat) were determined.
Total level of HBCDDs in serum was quantified by gas
chromatography with mass spectrometric detection (median
0.5 ng/g fat). HBCDD diastereomeric and enantiomeric
patterns were determined by liquid chromatography with
mass spectrometric detection. The dominating stereoisomer
was (-)R-HBCDD, but 1-3% of ç-HBCDD was also
detected in the serum samples.
Introduction
While it is established that endocrine disruption occurs in
wildlife for a range of persistent organic pollutants (POPs),
it has not yet been possible to confirm such effects in humans
(1). Still, there are numerous indications that such effects
can play a role in human health. For example, several
polychlorinated biphenyls (PCBs) have experimentally shown
the ability to act as endocrine disrupting compounds (EDCs).
PCBs and their hydroxylated metabolites (OH-PCBs) induce
decreased peripheral vitamin A and thyroxin (T4) levels in
rodents and induce microsomal enzyme activities (2). PCBs
have also been suggested to influence sperm quality (3, 4)
and possibly induce type 2 diabetes mellitus (5, 6). More
recently polybrominated diphenyl ethers (PBDEs) and
hexabromocyclododecanes (HBCDDs) have come into focus
due to increasing exposure levels (7-9) and concern about
their potential health effects (10-12). Endocrine disruption,
e.g., reproductive effects and developmental neurotoxicity
in rodents, is the principle effect causing concern (2,10-13).
So far PBDEs have been the most studied group of brominated
flame retardants, whereas data on HBCDDs are still scarce
(10, 14).
A potential effect of human endocrine disruption may be
osteoporosis as indicated in seals from the Baltic Sea (15).
Fractures have become more common among elderly people
all over the world, especially in northern Europe (16). Many
factors influence the risk of fractures, such as age, menopause,
heredity (17), and lifestyle habits (physical activity, smoking,
alcohol intake, and diet) (18). Animal data show that dioxin-
like POPs may impair normal bone metabolism and min-
eralization, as well as reduce collagen content and serum
osteocalcin levels, which result in increased bone fragility
(19-22).
Fatty fish from the Baltic Sea is a major source of POP
exposure for the population in Sweden and other countries
around the Baltic Sea (23, 24). In a register-based study there
was a significantly increased risk for vertebral fractures among
fishermen’s wives from the Swedish east coast as compared
with fishermen’s wives from the west coast. Fatty fish from
the Baltic Sea is more contaminated with POPs compared to
fish caught off the Swedish west coast (24). In a questionnaire
study there were no differences in fracture incidence between
east and west coast fishermen or fishermen’s wives (25).
However, for east coast fishermen’s wives incidence of
osteoporotic fractures correlated with consumption of fatty
fish from the Baltic Sea (25). A clinical examination of 196
east coast fishermen and 184 east coast fishermen’s wives
showed no association between serum levels of 2,2′,4,4′,5,5′-
hexachlorobiphenyl (CB-153), a biomarker for PCB, or p,p′-
DDE and bone mineral density (BMD) or biochemical
markers of bone metabolism (26).
The objectives of the present study were as follows: (1)
to assess serum levels of some selected environmental
pollutants (CB-153, OH-PCBs, PBDEs, and HBCDDs) in a
group of Swedish middle-aged and elderly women; (2) to
evaluate the impact of potential determinants for the inter-
individual variations in serum concentrations of the selected
environmental pollutants; and (3) to investigate the associa-
tions between these pollutants and bone density and
biochemical markers of bone metabolism.
Materials and Methods
Study Population and Interview. A previously established
cohort of wives and ex-wives of professional fishermen from
the Swedish east coast (27, 28) was approached for this study.
In 2000, postal questionnaires were sent to 1291 Swedish
subjects born 1920-1954. There were 779 women (77%) who
responded to the questionnaire. Out of these, 596 women
were positive to participate in future studies. A subset of 184
women was invited and participated in a study mainly focused
on the association between CB-153 and p,p′-DDE in serum
and bone mineral density (26), but also comprised by other
potential health effects of POP exposure. Details of the
recruitment process and non-participant analysis have been
given elsewhere (26). A subset of 53 women was selected for
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the present study. The selection criterion was to include those
with highest and lowest BMD measurement, to ensure
contrast in outcome measure. The overlap between the
subjects analyzed for CB-153, p,p′-DDE, and OH-PCBs and
those analyzed for PBDEs and HBCDDs was almost complete,
as serum from 50 of these women was analyzed for each
compound. The participants were asked about individual
factors that potentially might affect the concentrations of
pollutants in serum and bone metabolism (Table 1). Data for
calculation of the present body mass index (BMI) and as it
was at the age of 25 were collected for each participant. All
women had reached menopause. The study was performed
in accordance with the Declaration of Helsinki and approved
by The Lund University Ethic’s Committee. All participants
provided written informed consents.
BMD Measurement. BMD (g/cm2) was measured in the
distal section of the forearm (radius and ulna) using dual
energy X-ray absorptiometry (DXA), as described elsewhere
(26).
Blood Sampling. Blood was drawn between 8 and 10 a.m.
after 12 h fasting, into sterile Vacutainer glass tubes (BD
Vacutainer, Plymouth, UK). Sera were separated by cen-
trifugation (4000 rpm, 10 min) and transferred to glass tubes
before being stored at -80 °C until analysis.
Chemicals. CB-153 and 13C12-labeled CB-153 were pur-
chased from Riedel-deHae¨n (Seelze, Germany) and Cam-
bridge Isotope Laboratories (CIL, Andover, MA), respectively.
All OH-PCBs and PBDE congeners applied as internal and
external standards for identification and quantification were
synthesized in-house (29, 30). The external standards for
identification of R-, â-, and ç-HBCDD isomers were pur-
chased from CIL. All chemicals were of the best available
quality. Diazomethane was synthesized as described by Fieser
et al. (31) from N-methyl-N-nitroso-p-toluene sulfone amide
(Sigma-Aldrich, Stockholm, Sweden) as starting material, and
kept in diethyl ether and stored in a freezer at -20 °C until
use.
Chemical Analysis. Determination of CB-153, 4-hydroxy-
2,3,3′,4′,5-pentachlorobiphenyl (4-OH-CB107), 4-hydroxy-
2,2′,3,4′,5,5′-hexachlorobiphenyl (4-OH-CB146), and 4-hy-
droxy-2,2′,3,4′,5,5′,6-heptachlorobiphenyl (4-OH-CB187) in
serum samples (n ) 53) was performed at Lund University.
Analyses of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47),
2,2′,4,4′,6-pentabromodiphenyl ether (BDE-100), 2,2′,4,4′,5-
pentabromodiphenyl ether (BDE-99), 2,2,4,4′,5,6′-hexabro-
modiphenyl ether (BDE-154), 2,2′,4,4′,5,5′-hexabromodi-
phenyl ether (BDE-153), decabromodiphenyl ether (BDE-
209), and of total 1,2,5,6,9,10-hexabromocyclododecane (sum
of R-, â-, and ç-HBCDD), in serum samples (n ) 50) were
performed at Stockholm University.
The serum (1 mL) levels of CB-153 were determined as
previously described (3, 4). The method applied for the
cleanup and analysis of OH-PCBs, PBDEs, and HBCDDs in
serum (5 mL) is described by Hovander and co-workers (32),
with some modification for the PBDE and HBCDD analysis,
i.e., (1) no partitioning was performed with potassium
hydroxide (32), due to the alkaline instability of HBCDD,
and (2) to exclude the majority of the PCBs and remaining
lipids in the PBDE and HBCDD extract, a fractionation was
performed, applying a silica gel (0.7 g) column (33). The first
fraction of hexane (3 mL) was discarded, and the next fraction,
dichloromethane (5 mL), was collected.
The OH-PCBs were analyzed by GC-MS on a DB-1 (30
m) column with GC oven programmed from 100 °C to 210
°C (10 °C/min) and to 310 °C (30 °C/min). PBDE congeners
and HBCDDs (sum of R-, â-, and ç-HBCDD) were analyzed
by GC-MS on a DB-5 column (15 m). The injector was
programmed from 60 °C (1 min) to 300 °C (150 °C/min, 22
min). The GC oven was programmed from 80 °C (1 min) to
300 °C (15 °C/min, 10 min). MS was run in electron capture
negative ionization (ECNI) mode with selected ion monitoring
(SIM) where CB-153 was monitored at m/z 360, 13C12-labeled
CB-153 was monitored at m/z 372, 4-OH-CB107, 4-OH-
CB146, 4-OH-CB187, and 4-OH-CB193 were monitored at
m/z 341.5, 375.5, 409.5, and 409.5, respectively, and the PBDE
congeners and HBCDD were monitored for the bromide
isotopes m/z 79 and 81.
The PBDE/HBCDD extracts were later pooled (n ) 25,
125 mL/pool) for stereoisomer determination, by LC/MS-
MS performed at the Norwegian Institute of Public Health,
using a published method (34). Diastereomers were separated
on a Symmetry C18 LC-column with a mobile phase com-
position programmed from water/methanol (60%:40%) at
250 íL/min in 5 min to methanol (100%), and held for 7 min.
Enantiomers were separated on a chiral (NUCLEODEX beta-
PM) LC-column using mobile phase programmed from
water/methanol/acetonitrile (30%:20%:50%), 0.5 min, 500
íL/min in 10 min, to methanol/acetonitrile (45:55), and held
for 8 min. MS was operated in electrospray ionization negative
ion mode using multiple reaction monitoring (MRM).
Quality Control. The recovery of PBDE congeners and
HBCDD was tested in a separate recovery study with low (1
ng) and high (10 ng) doses added. Mean recovery for low
dose was 86-93% and for high dose was 75-98% depending
on congener. The recovery of added surrogate standard to
all samples was between 67 and 116%. The analysis of CB-
153 was part of an inter-comparison program (3). The
obtained results were within the tolerance limits (2x standard
deviation).
TABLE 1. Background Characteristics of 53 Fishermen’s Wives
from the Swedish East Coast
n % median 5% 95%
potential determinants for persistent
organic pollutant concentration
age (yr) 62 52 81
current body mass index (kg/m2) 27 21 42
change in body mass index since
age 25 (% increase)
18 0 73
current consumption of fatty fish
from the Baltic Sea
(meals/month)
2 0 12
outcome variables
bone mineral density (g/cm2) 0.44 0.24 0.61
S-Osteocalcin (íg/L) 28 12 58
S-CTX (ng/L) 386 114 877
potential confounders for the association between
persistent organic pollutants and
bone mineral density, osteocalcin and CTX
body height (cm) 163 156 173
current body weight (kg) 71 55 112
body weight at age 25 (kg) 63 46 75
body mass index at age 25 (kg/m2) 22 18 27
age at menopause 50 44 56
length of fertile period (years) 36 29 43
current hormone replacement
therapy
10 19
history of fracturea 2 4
heredity for fractureb 10 19
low physical activity at work at
25 and 35 yrs of agec
3 6
currently low physical activityd 7 13
current smoking (cigarettes/day) 0 0 15
cumulative cigarette smoking
over life (pack-years)
0 0 33
current alcohol consumption
(g/month)
37 0 362
a Osteoporotic fracture after 50 years of age. b Parents or siblings.
c Definedasmostlysittingorstandingwith lowmuscleactivity. d Defined
as mostly sitting or standing with low muscle activity at work and
participating in other physical activities (such as cycling, walking,
gardening, etc.) less than 7 h per week.
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The analytical limits of detections (LOD, s/n ) 3) for CB-
153, 4-OH-CB107, 4-OH-CB146, and 4-OH-CB187 were
estimated to 7.3 ng/g fat, 0.02 ng/mL, 0.02 ng/mL, and 0.01
ng/mL respectively. The LOD (s/n ) 5) was 0.012-0.024 ng/g
fat for BDE-47, -99, -100, -153, and -154, and 0.12 pg/g fat
for BDE-209 and HBCDD. LODs (s/n ) 3) of R-, â-, and
ç-HBCDD diastereomers were 0.03, 0.06, and 0.03 ng/g fat,
respectively. For enantiomers, LODs were 1.5 ng/g fat for
(+)R-HBCDD and (+)â-HBCDD and 0.7 ng/g fat for (+)ç-
HBCDD. Limit of quantification (LOQ) was defined as 10
times the noise level or 3 times background blank levels.
Background levels were detected for BDE-47 (0.12 ng/g fat),
BDE-99 (0.06 ng/g fat), and BDE-209 (0.06 ng/g fat). In all
analyses background levels found in blank samples were
subtracted from measured values.
Quality control was performed by inter-laboratory cali-
bration of OH-PCB analysis between three laboratories.
Coefficient of variation (CV) between mean reported levels
from each laboratory was 2-15%, and within laboratories
was 3-13% (Stockholm), 1.5-17% (Lund), and 5-9% (Am-
sterdam). Intra-laboratory quality control of PBDE and
HBCDD analysis was performed via repeated analysis of
reference material (35). The interassays CV were 1-12% for
BDE-47, -99, -100, -153, and -154 and 20-28% for BDE-209
and HBCDD.
Enzymatic Determination of Serum Lipids. Serum
concentrations of triglycerides and cholesterol were deter-
mined enzymatically (36). Based on calculations reported
by Rylander and co-workers (37) the total lipid concentration
in serum (g/L) was calculated by the following equation:
Total lipids ) 0.9 + 1.3(Ctriglycerides + Ccholesterol).
Analyses of Biochemical Markers of Bone Metabolism.
Crosslaps (CTX) and osteocalcin in serum were determined
with immunoassays. Methods and imprecision of analyses
have been described elsewhere (26).
Statistics. Age, current BMI, relative change in BMI from
BMI at 25 years of age (% increase), and intake of fatty fish
from the Baltic Sea were considered as possible predictors
of serum concentrations of the POP biomarkers. In order to
build multivariate models including these possible predictors,
stepwise regression (backward) with p-to-include ) 0.10 was
used (SPSS for Windows version 12.0). Thus, in a first step,
all possible predictors were included in the model. The
variable that contributed the least to the total explained
variance was excluded if the p-value for its contribution was
>0.10. Residuals were checked using a normal probability
plot. If the assumption of normality was not met, a model
with log-transformed values was tried. The model based on
log-transformed values was found to be appropriate for 4-OH-
CB107, 4-OH-CB146, 4-OH-CB187, CB-153, BDE-47, BDE-
99, BDE-100, BDE-154, BDE-209, and “6PBDE but not for
BDE-153 and HBCDD. When the outcome is log-transformed,
interpretation of the slope of the regression line (â) is not
straight forward. However, using the formula 100(eâ - 1) the
percentage increase in the average value of the outcome per
unit increase in the predictor was calculated.
To evaluate a possible effect of the POP biomarkers (all
but CB-153, which has been analyzed previously (26) on
BMD), and serum concentrations of osteocalcin and CTX, all
biomarkers were dichotomized at their respective median
(Table 2), resulting in a low- and a high-exposed group. Since
none of the outcome variables fulfilled the normality criteria,
and since the number of observations was small, differences
between low and high exposure were evaluated using Mann-
Whitney’s U-test (StatXact-6). To evaluate possible con-
founding, pair-wise Spearman’s correlations between the
potential confounders in Table 1, and POP-biomarkers
(continuous variables), BMD, osteocalcin, and CTX were
calculated. If a variable was found to correlate (rS > 0.20)
with both the biomarker and the outcome, it was considered
as a confounder, and its dichotomized version (cut at the
median) was used to adjust the p-value. The analyses
regarding 4-OH-CB107, 4-OH-CB146, and 4-OH-CB187 were
performed using the wet weight concentrations, whereas all
other analyses were based on lipid adjusted concentrations.
Results below LOD were given a value of 0, and results below
LOQ were given a value of 0.5 LOQ.
The composition of enantiomeric HBCDD was expressed
as enantiomer fractions (EFs) calculated from the peak areas
(A) of enantiomers (() in a pair by the following formula:
Results
OH-PCB fresh weight concentrations are given in Table 2.
Lipid-adjusted concentrations of CB-153, PBDEs, and HB-
CDDs, expressed both in a molar scale (pmol/g fat) and on
a weight basis (ng/g fat) are also given in Table 2. The median
concentrations of the three OH-PCBs were rather similar
(range 0.47-0.68 ng/mL). Among the PBDEs the highest
median concentration was reported for BDE-153 (1.1 ng/g
fat), followed by BDE-47 (0.9 ng/g fat), whereas on a molar
basis BDE-47 level (1.9 pmol/g fat) was followed by BDE-153
(1.7 pmol/g fat) and then similar concentrations for BDE-
154 (0.52 pmol/g fat), BDE-100 (0.51 pmol/g fat), BDE-209
(0.48 pmol/g fat), and BDE-99 (0.35 pmol/g fat).
The median concentration for HBCDDs was 1/500 of CB-
153, while only half of the BDE-47 level (cf. Table 2). Among
the HBCDDs (Figure 1) R-HBCDD is the dominating dias-
tereomer in the serum samples but ç-HBCDD was also
detected (1-3%) in the samples. (-)R-HBCDD was identified
as the dominating HBCDD enantiomer. The EF was estimated
to be between 0.17 and 0.23 (Figure 2).
Age was positively associated with all three OH-PCBs,
CB-153, and HBCDD, but only with BDE-154 among the
PBDEs (Table 3). It cannot be excluded that the BDE-154
chromatography was influenced by coeluting 2,2′,4,4′,5,5′-
hexabromobiphenyl. BDE-153 was negatively associated with
current BMI, which means there were higher serum con-
centrations in relatively lean women. No significant associa-
tion was observed between current BMI and any of the other
compounds. Significant negative associations between per-
TABLE 2. Concentrations of CB-153 (n ) 53), OH-PCBs (n )
50), PBDEs and HBCDDs (n ) 50) in Human Serum
median 5% 95% minimum maximum
fat content (%) 0.65 0.51 0.83 0.48 0.86
CB-153 (ng/g fat) 260 98 500 70 620
4-OH-CB107 (ng/mL) 0.54 0.17 1.9 0.12 3.3
4-OH-CB146 (ng/mL) 0.68 0.26 1.4 0.19 1.8
4-OH-CB187 (ng/mL) 0.47 0.21 1.0 0.14 1.4
BDE-47 (ng/g fat) 0.91 0.29 5.9 0.27 8.1
BDE-47 (pmol/g fat) 1.9 0.59 12 0.55 17
BDE-99 (ng/g fat) 0.20 <0.18a 1.9 <0.18a 3.1
BDE-99 (pmol/g fat) 0.35 <0.30a 3.4 <0.30a 5.5
BDE-100 (ng/g fat) 0.29 0.11 1.0 0.08 2.6
BDE-100 (pmol/g fat) 0.51 0.20 1.8 0.14 4.7
BDE-153 (ng/g fat) 1.1 0.46 2.5 0.29 4.7
BDE-153 (pmol/g fat) 1.7 0.71 3.9 0.44 7.2
BDE-154 (ng/g fat) 0.33 0.19 1.0 0.17 1.3
BDE-154 (pmol/g fat) 0.52 0.30 1.6 0.26 2.1
BDE-209 (ng/g fat) 0.46 <0.18b 3.0 <0.18b 3.3
BDE-209 (pmol/g fat) 0.48 <0.18b 3.2 <0.18b 3.5
“6PBDE (ng/g fat) 3.6 1.5 12 1.1 20
“6PBDE (pmol/g fat) 5.8 2.5 24 1.8 35
HBCDDs (ng/g fat) 0.46 <0.24c 1.2 <0.24c 3.4
HBCDDs (pmol/g fat) 0.71 <0.37c 1.9 <0.37c 5.4
a n < LOQ (LOD) ) 14 (0). b n < LOQ (LOD) ) 7 (10). c n < LOQ (LOD)
) 6 (1).
ER )
(+)A
(-)A + (+)A
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cent increases in BMI from age 25 to the current situation
were observed for all three OH-PCBs and for CB-153, but
positive associations were seen for BDE-99 and BDE-100.
Current consumption of fatty fish from the Baltic Sea was
positively associated with CB-153 in serum, but not with any
of the other POPs analyzed, indicating the fatty fish is not
a major source of these compounds.
The linear regression models explained between 26 and
34% of the variance for the different OH-PCB congeners,
which was lower than 41% for CB-153, but higher than for
the PBDE congeners (8-24%) and HBCDDs (11%). None of
the potential determinants explained any variation in BDE-
209 concentrations.
There were negative associations between high serum
concentrations of 4-OH-CB146 and 4-OH-CB187, respec-
tively, and BMD, but when adjustments were made for age,
weight, and BMI, no associations remained (Table 4). There
were no other significant associations between the exposure
and outcome variables.
Discussion
CB-153 is a well-established biomarker for PCB exposure
and represents 25% of total PCB (38, 39), suggesting a total
PCB concentration in serum of 280-2500 ng/g fat in the
present cohort. OH-PCB levels have been reported to
constitute between 5% and 40% of the total PCB on a fat
basis (23, 35, 40, 41). “3OH-PCBs as presented in this study
are on a level similar to that of CB-153, and within the
previously mentioned range. Both CB-153 and “3OH-PCB
are considerably higher than reported serum levels in general
populations in Europe at the same time period (40,42-44),
but comparable with CB-153 concentrations in an elderly
population of Swedish women (54-75 years old) (45). The
PCB levels and hydroxylated metabolites are also comparable
with a hot-spot exposure area in Slovakia (46), and in the
Faeroe Islands (47), as well as with high and low fish
consumers in Sweden, Latvia (23), and Finland (48). CB-153
levels correlate significantly with age of the individuals as
reported earlier (23, 42, 45). It is thus expected that OH-PCB
levels show similar trends (23).
In the present study, PBDEs did not correlate with age,
which is in accordance with previous reports on human
serum (23,49-51), but interestingly HBCDD does correlate
with age. HBCDD total body half-life in humans has been
estimated to 64 days, which is considerably lower than half-
lives for tetraBDEs-hexaBDEs (1-10 years) (52), but longer
than the apparent plasma half-life of BDE-209 (15 days) (53).
Possibly, this difference can be explained by a continuous
and ongoing use of HBCDD while the PBDE exposure has
been disrupted (7, 54). This reasoning is supported by the
results of increasing HBCDD concentrations in human milk
(7) and guillemot eggs (54).
PBDE congener levels in the fishermen’s wives are
comparable to or lower than those of other recently
conducted studies on human serum in Europe (44, 49, 55).
The “6PBDE levels analyzed in human serum in this study
were between 2 and 35 pmol/g fat. Studies on PBDE levels
in human tissue have commonly reported BDE-47 as the
dominating congener (8). In the current study BDE-153
concentrations were similar to BDE-47 which has been
FIGURE 1. Separation of HBCDD diastereomers in two pooled samples (n ) 25) of human serum as performed by LC/MS-MS (Symmetry
C18 LC-colum).
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reported in several other studies (7, 35, 56, 57). This might
be due to the suggested three times longer half-life of BDE-
153 than of BDE-47 (52), possibly combined with a positive
effect of the voluntary phase-out of PentaBDE in Sweden, as
early as the beginning of the 1990s (10). PentaBDE is a major
source of BDE-47 (30% of the mixture) whereas BDE-153 is
a minor component in both PentaBDE and OctaBDE techni-
cal mixtures (10). Further, it cannot be excluded that abiotic
decomposition or metabolism of BDE-209 to lower bromi-
nated PBDEs, such as BDE-153, can be a contributing factor
to elevated BDE-153 concentrations (58-60).
There are few analyses conducted on HBCDDs in human
tissue. In 2003 HBCDDs were for the first time identified and
quantified in breast milk from a Swedish background
population (61) and from a Norwegian population with high
fish intake (62), and in 2004 in maternal and cord blood from
The Netherlands (57) and in Mexican breast milk and blood
(63). All HBCDD concentrations were in the same range as
those reported here for the fishermen’s wives (0.3-5.4 pmol/g
fat). A time trend study on human milk levels of HBCDDs
and PBDEs in Swedish mothers was recently finished, in
which an increasing trend of HBCDDs was observed, starting
from the mid 1980s, but leveling off over the last couple of
years (7). The HBCDD concentrations in mothers’ milk were
below 1 pmol/g fat throughout the study period.
The technical mixture consist mainly of ç-HBCDD (80%)
while biological samples most commonly seem to contain
R-HBCDD as the dominating isomer (34, 64, 65). It has been
suggested that the exclusive presence of R-HBCDD is due to
a significant metabolism of â-HBCDD and ç-HBCDD by
cytochrome P450 (64). In the current survey (-)R-HBCDD
was the dominating enantiomer in human serum with an EF
of around 0.2 indicating enantioselective processes in the
accumulation of (-)R-HBCDD. We are not yet able to explain
this enantioselectivity. Between 1 and 3% ç-HBCDD was
detected in these human samples which may reflect an active
FIGURE 2. Separation of HBCDD enantiomers in one pool (n ) 50) of human serum samples as performed by LC/MS-MS (chiral NUCLEODEX
beta-PM LC-column).
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or present source of exposure. To the best of our knowledge
this is the first time HBCDD isomers and the enantiomer
ratio have been reported in human serum.
No associations between BMD or the biochemical markers
of bone metabolism and the analyzed environmental pol-
lutants were found. One caveat with this conclusion is the
limited number of samples, which hampers evaluation of
weak or moderate associations. On the other hand, if there
had been strong associations they would have been detected.
In this study a slight modification of a well-established
analytical method was applied, owing to the special demands
of both HBCDD and BDE-209, e.g., instability in alkaline
solution and sufficient cleanup. A major problem for most
brominated flame retardants, but in particular BDE-209, is
background contamination of the samples. Solvent blank
levels were low and highly sufficient for PBDE analysis, with
instrumental LOQ between 0.008-0.12 pg/injection for BDE-
47 to BDE-154. LOQ for HBCDDs and BDE-209 was 0.08
pg/injection.
Stereoisomers cannot be separated by GC and analysis
must be performed by LC. However, higher LOD (1-2 pg/
injection) together with 20 times larger injection volume
demands a larger sample volume to detect trace levels of
HBCDD. In this study, 125 mL of serum sample was used
(end volume 0.5 mL) for diastereomer determination. Further,
it has been reported that analyses of total HBCDD performed
on GC and LC are in good agreement (66, 67). Hence the
present method is indeed suitable for analysis of low
concentrations of HBCDDs and PBDEs in human blood.
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TABLE 3. Linear Multiple Regression Coefficients (â with p-values) from Backward Stepwise Regression for Determinants for
Human Serum Levels of CB-153 (n ) 53), OH-PCBs (n ) 50), and PBDEs and HBCDDs (n ) 50)
Age (yrs)
Current body mass index
(kg/m2)
Change in body mass index
from age 25 (% increase)
Baltic Sea fatty fish
(meals/month)
â p % incc â p % incc â p % incc â p % incc
explained
variance
(%)
CB-153a 0.027 0.001 2.74 0.029 0.07 2.94 -0.011 0.01 -1.09 0.035 0.021 3.56 41
4-OH-CB107a 0.031 0.02 3.15 0.058 0.06 5.97 -0.018 0.02 -1.78 NIb 26
4-OH-CB146a 0.025 0.008 2.53 NIb -0.009 0.004 -0.90 NIb 34
4-OH-CB187a 0.019 0.03 1.92 NIb -0.008 0.01 -0.77 NIb 26
BDE-47a NIb NIb 0.011 0.07 1.11 NIb 8
BDE-99a NIb -0.184 0.08 -16.8 0.075 0.02 7.79 -0.150 0.09 -13.9 19
BDE-100a NIb -0.057 0.06 -5.54 0.023 0.006 2.33 NIb 18
BDE-153 NIb -0.075 0.002 0.011 0.09 1.11 NIb 25
BDE-154a 0.020 0.02 2.02 NIb NIb NIb 12
BDE-209a NIb NIb NIb NIb
“6PBDEa NIb -0.057 0.03 -5.54 0.016 0.04 1.61 NIb 11
HBCDDs 0.023 0.03 2.33 NIb NIb NIb 11
a Based on log-transformed values. b NI ) Not included. The variable did not fulfill the criteria to be included in the final model. c Percentage
increase in the average value of the outcome per unit increase in the predictor. Calculated using the formula 100(eâ - 1) if the outcome is
log-transformed.
TABLE 4. Effect of OH-PCBs, PBDEs, and HBCDDs in Human Serum, Respectively, on Bone Mineral Density and Serum
Concentrations of Osteocalcin and Crosslaps
Bone mineral density (g/cm2) Osteocalcin (íg/L) CTX (ng/L)
median 2.5% 97.5% pa adj pb median 2.5% 97.5% pa median 2.5% 97.5% pa
4-OH-CB107 low (<0.54 ng/ml) 0.51 0.27 0.70 24 11 58 383 71 805
high (>0.54 ng/ml) 0.32 0.20 0.69 0.14 29 12 73 0.58 485 193 1351 0.24
4-OH-CB146 low (<0.68 ng/ml) 0.52 0.21 0.70 20 12 58 374 71 805
high (>0.68 ng/ml) 0.32 0.20 0.69 0.03 0.46 30 11 73 0.07 485 101 1351 0.12
4-OH-CB187 low (<0.47 ng/ml) 0.52 0.21 0.70 20 12 58 374 114 805
high (>0.47 ng/ml) 0.32 0.20 0.69 0.02 0.34 30 11 73 0.21 411 71 1351 0.46
BDE-47 low (<0.92 ng/g) 0.33 0.20 0.69 30 11 79 459 101 814
high (>0.92 ng/g) 0.52 0.21 0.70 0.07 22 13 73 0.36 323 71 1351 0.29
BDE-99 low (<0.20 ng/g) 0.32 0.20 0.69 30 11 79 425 101 1351
high (>0.20 ng/g) 0.51 0.21 0.70 0.24 22 13 73 0.19 374 71 1204 0.64
BDE-100 low (<0.287 ng/g) 0.33 0.20 0.69 29 11 79 425 101 814
high (>0.287 ng/g) 0.51 0.21 0.70 0.43 22 13 73 0.51 374 71 1351 0.57
BDE-153 low (<1.08 ng/g) 0.50 0.24 0.70 27 12 79 411 165 814
high (>1.08 ng/g) 0.44 0.20 0.61 0.35 29 11 73 0.81 383 71 1351 0.72
BDE-154 low (<0.335 ng/g) 0.50 0.20 0.69 29 12 79 425 163 814
high (>0.335 ng/g) 0.44 0.21 0.70 0.85 22 11 73 0.38 288 71 1351 0.19
BDE-209 low (<0.46 ng/g) 0.43 0.20 0.61 30 12 58 478 200 1351
high (>0.46 ng/g) 0.48 0.21 0.70 0.92 20 11 79 0.10 298 71 1204 0.12
“6PBDE low (<3.67 ng/g) 0.33 0.20 0.69 27 11 79 459 101 814
high (>3.67 ng/g) 0.51 0.21 0.70 0.30 28 13 73 0.79 323 71 1351 0.36
HBCDDs low (<0.46 ng/g) 0.35 0.20 0.69 29 11 73 418 101 1204
high (>0.46 ng/g) 0.52 0.24 0.70 0.51 27 12 79 0.73 374 71 1351 0.46
a p-value for low vs high (Mann-Whitney’s U-test). b p-values adjusted for age, weight, and BMI. Adjusted p-values are given only when
unadjusted p-values were >0.05
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